Bone · FDA Approved
Abaloparatide (Tymlos)
FDA-approved
01 · Overview
A synthetic 34-amino acid peptide analog of parathyroid hormone-related protein (PTHrP 1-34). In cell studies abaloparatide binds more selectively than PTH (1-34) to the RG conformation of the PTH1 receptor, producing more transient cAMP signaling, a proposed explanation for its anabolic effect with less bone resorption and calcium mobilization (PMID 26562265).
It increases bone mineral density at the spine and hip (PMID 27533157).
02 · Research summary & key findings
FDA-approved in 2017 for postmenopausal women with osteoporosis at high fracture risk. The 18-month ACTIVE trial found fewer new vertebral and nonvertebral fractures with abaloparatide than placebo, and a lower incidence of hypercalcemia than teriparatide (3.4% vs. 6.4%) (PMID 27533157). In ACTIVExtend, fracture reductions persisted when patients switched to alendronate (PMID 28160873). The ATOM trial showed bone density gains in men with osteoporosis (PMID 36190391).
03 · Regulatory status
Abaloparatide (Tymlos) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Abaloparatide (Tymlos) is an FDA-approved medicine prescribed for the conditions on its label. It is not part of our intake, so we do not propose protocols for it. If you think it may be relevant to you, talk to your own doctor. How to ask your doctor.
Looking for a lawful, clinician-prescribed option for injury recovery and tissue repair?
Abaloparatide (Tymlos) is prescribed for the conditions on its label, and it is not part of our intake. If you are working on injury recovery and tissue repair, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection (daily)
References
- [1]Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling Endocrinology, 2016. PMID 26562265
- [2]Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial JAMA, 2016. PMID 27533157
- [3]Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial Mayo Clin Proc, 2017. PMID 28160873
- [4]The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial J Bone Miner Res, 2022. PMID 36190391
Primary literature
- PubMed: "Abaloparatide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Abaloparatide"
Registered interventional and observational studies, including status and phase.
- PubChem: "Abaloparatide"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Bone
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.